Circulating tumor DNA

Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening

Retrieved on: 
木曜日, 5月 30, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Incidence, DNA, Plasma, MBC, Circulating tumor DNA, Helmy Eltoukhy, PIK3CA, Neoplasm, Nucleic acid thermodynamics, Chinese, Interim, Biomarker, ASCO, ESR1, Society, Liquid biopsy, ABC, Annual general meeting, Medical imaging

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from 16 studies highlighting the role of Guardant blood tests and real-world data in advancing precision oncology and cancer screening at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, May 31-June 4 in Chicago.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from 16 studies highlighting the role of Guardant blood tests and real-world data in advancing precision oncology and cancer screening at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, May 31-June 4 in Chicago.
  • Additional studies will present data supporting the application of genomic and epigenomic biomarkers in areas such as minimal residual disease detection and cohort characterization.
  • “The robust data we present at ASCO will further demonstrate the important scientific and clinical developments in cancer care that are possible using liquid biopsy,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO.
  • For more information and updates from the meeting, follow Guardant Health on LinkedIn and X (Twitter) or visit ASCO booth #28115.

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

Retrieved on: 
水曜日, 5月 15, 2024
Ribociclib, Half-life, Neutropenia, Pharmacokinetics, MTD, DNA, Plasma, Data, Toxicity, Index, Circulating tumor DNA, Safety, QT interval, Breast cancer, Neoplasm, Congress, Incidence, Partial, ESR1, Poster, Woman, Fatigue, CBR, Breast, Webcast, Pharmaceutical industry

These results, as of the data cut-off of March 13, 2024, will be presented on May 16, 2024, in a poster session at the 2024 ESMO Breast Cancer Annual Congress in Berlin, Germany (ESMO Breast).

Key Points: 
  • These results, as of the data cut-off of March 13, 2024, will be presented on May 16, 2024, in a poster session at the 2024 ESMO Breast Cancer Annual Congress in Berlin, Germany (ESMO Breast).
  • Palazestrant did not affect ribociclib drug exposure and ribociclib had no clinically meaningful effect on palazestrant drug exposure.
  • Findings from this study support the continued clinical development of palazestrant in combination with ribociclib for the first-line treatment of ER+/HER2- advanced or metastatic breast cancer.
  • Olema will host a webcast and conference call for analysts and investors to review the data being presented at ESMO Breast Cancer Annual Congress 2024 today, Wednesday, May 15, 2024, at 8:00 a.m.

Foundation Medicine Announces Details of Over 20 Presentations at the 2024 ASCO® Annual Meeting

Retrieved on: 
金曜日, 5月 24, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, ERBB2, Patient, Lung, Doctor of Philosophy, Cancer, DNA, Booth, AKT1, MBC, PBO, HER2, Circulating tumor DNA, Prevalence, PIK3CA, Endometrial cancer, TALA, Neoplasm, MD, Abstract, CGP, ASCO, Foundation Medicine, Talazoparib, RNA, Society, PTEN, Breast, Annual general meeting, Medical imaging

Foundation Medicine, Inc ., today announced that 22 new pieces of research from its robust oncology diagnostics portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago.

Key Points: 
  • Foundation Medicine, Inc ., today announced that 22 new pieces of research from its robust oncology diagnostics portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago.
  • “We are also excited to demonstrate our new RNA sequencing capabilities and spotlight the expanding utility of ctDNA to inform treatment decision making through a simple blood sample.”
    The following is a complete list of Foundation Medicine abstracts that will be presented.
  • To access the abstracts being presented at ASCO, please visit ASCO.org/abstracts .
  • Follow Foundation Medicine on LinkedIn , X and Instagram for more updates from #ASCO24 and visit us in person at Booth #22031.

Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024

Retrieved on: 
水曜日, 5月 22, 2024
Biotechnology, Health, Genetics, Health Technology, Oncology, Genomics, Patient, Prevalence, DNA, NeXT, Colorectal cancer, Circulating tumor DNA, Ultra, Breast cancer, Neoplasm, MRD, ASCO, CRC, THP, Kinetics, Society, Daphne, Annual general meeting, PSNL, Medical imaging

“As the body of studies continues to grow that demonstrates the role our ultra-sensitive MRD test, NeXT Personal, can play in identifying recurrent cancer early, we were honored to learn that two Personalis studies were selected as podium presentations at ASCO 2024’s Clinical Science Symposium”, said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis.

Key Points: 
  • “As the body of studies continues to grow that demonstrates the role our ultra-sensitive MRD test, NeXT Personal, can play in identifying recurrent cancer early, we were honored to learn that two Personalis studies were selected as podium presentations at ASCO 2024’s Clinical Science Symposium”, said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis.
  • The two studies that were selected to appear as podium presentations are:
    Overview: Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer.
  • Details of the Personalis abstracts are outlined below, and further details about the poster presentations can be found here .
  • Overview: Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay.

Foresight Diagnostics Co-Founder Dr. David Kurtz Joins Company as Chief Medical Officer and Head of Research

Retrieved on: 
水曜日, 5月 1, 2024
Neoplasm, Stanford University, Foresight, Genomics, CMO, College of Engineering (KNUST), MRD, Doctor of Philosophy, Lymphoma, Entrepreneurship, DNA, Translation, Principal, Circulating tumor DNA, Assistant, Molecular biology, Growth, Liquid biopsy

BOULDER, Colo., May 1, 2024 /PRNewswire/ -- Foresight Diagnostics™, a leading diagnostics company specializing in the development of ultra-sensitive minimal residual disease (MRD) detection, announced today the appointment of David Kurtz, MD, PhD, as its new Chief Medical Officer (CMO) and Head of Research.

Key Points: 
  • BOULDER, Colo., May 1, 2024 /PRNewswire/ -- Foresight Diagnostics™, a leading diagnostics company specializing in the development of ultra-sensitive minimal residual disease (MRD) detection, announced today the appointment of David Kurtz, MD, PhD, as its new Chief Medical Officer (CMO) and Head of Research.
  • "We are thrilled to have Dr. Kurtz join Foresight to lead our research and development efforts and steer our medical affairs strategy," said Jake Chabon, CEO and Co-Founder of Foresight.
  • During this time, Dr. Kurtz ran an independent research laboratory focused on translational genomics.
  • Clinically, Dr. Kurtz is a medical oncologist who specializes in the treatment of non-Hodgkin lymphomas.

United States Liquid Biopsy Market Report 2023 and 2024-2032 Featuring Thermo Fisher Scientific, Roche Diagnostics, Bio-Rad, Biocept, Biocartis, Myriad Genetics, Exact Sciences, NeoGenomics, Quest - ResearchAndMarkets.com

Retrieved on: 
火曜日, 4月 23, 2024
Biotechnology, Surgery, Health, Genetics, Oncology, Liquid biopsy, Neoplasm, Nucleic acid thermodynamics, FDA, Urine, Breast cancer, CGP, NTRK, Prostate cancer, NIH, Woman, Blood, Entrectinib, Seminal vesicles, Gene, Liquid, Health care, Research, Plasma, Chinese, NGS, DNA, Lung, Incidence, Patient, Circulating tumor DNA, Diagnosis, Illumina, Inc., Biomarker, DCIS, NSCLC, Medical imaging

The "United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering.
  • The United States Liquid Biopsy Market value is foreseen to be around US$ 3.68 Billion by 2032.
  • These innovations enhance cancer detection and monitoring and propel the United States liquid biopsy market.
  • Breast cancer might stand out as a distinguished concern in the United States liquid biopsy market.

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

Retrieved on: 
金曜日, 4月 5, 2024
CD4, CD8, AMP, Development, Antigen, Immunotherapy, Colorectal cancer, Memory, Patient, Lung, GM-CSF, Biomarker, DNA, Epitope, Cancer, Granzyme B, BRAF, Lymph, IL2, Circulating tumor DNA, Phenotype, Neoplasm, Research and development, Immunization, Therapy, Vaccination, CRC, V600E, Immune system, Melanoma, Granzyme, Phase 1, Amphetamine, Nature Medicine, Annual general meeting, Vaccine

Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.

Key Points: 
  • Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.
  • A majority of patients who received the booster immunizations maintained or increased mKRAS-specific T cell responses relative to baseline.
  • The mKRAS-specific CD4 and CD8 T cells generated by ELI-002 exhibited increased cytotoxic function and development of favorable memory phenotype.
  • "Earlier data published in Nature Medicine demonstrate that our off-the-shelf lymph node-targeted cancer vaccine candidate, ELI-002, induces memory T cell responses.

Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite St

Retrieved on: 
月曜日, 4月 1, 2024
Lung cancer, Survival, Immunotherapy, Disease, Colorectal cancer, Progression-free survival, Medicine, Patient, Common, DNA, Aes, Cancer, Death, Doctor of Philosophy, Gritstone bio, MD, Kinetics, Induction chemotherapy, MSS, Circulating tumor DNA, VAF, Melanoma, PFS, Vaccine, Data, UCLA, Liver disease, Neoplasm, Pharmaceutical industry

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced positive preliminary data from the ongoing, signal seeking Phase 2 portion of the Phase 2/3 study evaluating GRANITE, its personalized neoantigen cancer vaccine, in front-line metastatic microsatellite stable colorectal cancer (MSS-CRC). The randomized, controlled, open-label study is designed to quantify the clinical benefit of maintenance therapy with GRANITE (GRT-C901/GRT-R902) in combination with immune checkpoint blockade in addition to fluoropyrimidine/bevacizumab versus fluoropyrimidine/bevacizumab alone. Overall progression free survival (PFS) data show an early trend in benefit for GRANITE patients (HR=0.82, [95% CI, 0.34-1.67]; 62% censored) and extended PFS benefit in high-risk patients (HR=0.52 [95% CI, 0.15-1.38]; 44% censored), in whom progression occurs faster. Circulating tumor DNA (ctDNA) analysis over several months of treatment shows the expected relationship with disease progression and favors GRANITE, while short-term ctDNA response analysis (molecular response as defined per protocol) did not demonstrate a difference between study arms. Gritstone bio successfully manufactured GRANITE product candidate for every eligible patient (i.e., 100% vaccine manufacturing success rate).

Key Points: 
  • Gritstone bio successfully manufactured GRANITE product candidate for every eligible patient (i.e., 100% vaccine manufacturing success rate).
  • “Today's preliminary Phase 2 results are highly encouraging and represent the first randomized trial evidence, albeit early, that a personalized neoantigen-directed vaccine can potentially drive efficacy in a metastatic ‘cold’ tumor.
  • Fortunately, long-term analysis demonstrates the expected correlation of ctDNA with clinical benefit and favors GRANITE patients.
  • This analysis was performed on 44 patients who received study treatment (control and GRANITE arms) and have available baseline ctDNA data.

Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer

Retrieved on: 
月曜日, 3月 18, 2024
Science, Other Science, Biometrics, Biotechnology, Oncology, Health, Genetics, Clinical Trials, ACT, Cordeliers, Survival, Colorectal cancer, Patient, DNA, Observation, Standard of care, Doctor of Philosophy, MD, FOLFOX, Gastroenterology, Circulating tumor DNA, NTRA, CRC, MRD, Neoplasm, Nursing

The study’s main objective is to determine the benefit of adjuvant chemotherapy (ACT) in stage II CRC patients with detectable circulating tumor DNA (ctDNA) post-surgery.

Key Points: 
  • The study’s main objective is to determine the benefit of adjuvant chemotherapy (ACT) in stage II CRC patients with detectable circulating tumor DNA (ctDNA) post-surgery.
  • Patients who are Signatera MRD-positive will be randomized to receive ACT (FOLFOX 6m) or pursue observation (no chemotherapy).
  • While the Japanese and U.S. trials evaluate the benefit of MRD-guided treatment in stage III and high-risk stage II CRC patients, the French trial is focused on stage II CRC.
  • “We believe this randomized study could establish a new standard of MRD-guided care in stage II colorectal cancer, potentially improving treatment decisions for thousands of patients.”
    Natera has joined the study in progress.

Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine

Retrieved on: 
水曜日, 3月 13, 2024
Health, Oncology, Clinical Trials, Medical Supplies, Harvard Medical School, Colonoscopy, Colorectal cancer, Helmy Eltoukhy, Survival rate, Massachusetts General Hospital, Cancer, Risk, Patient, Ageing, Evaluation, American Cancer Society, Neoplasm, Perception, DNA, MD, Circulating tumor DNA, Hospital, PMA, CRC, Large intestine, Multimedia, FDA, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240313547689/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240313547689/en/
    Shield (TM) from Guardant Health is a blood test for colorectal cancer screening for adults age 45-84 who are at average risk.
  • (Photo: Business Wire)
    “Over 50 million eligible Americans do not get recommended screenings for colorectal cancer, partly because current screening methods are inconvenient or unpleasant,” said AmirAli Talasaz, Guardant Health co-CEO.
  • The Shield test detects colorectal cancer signals in the bloodstream from DNA that is shed by tumors, called circulating tumor DNA (ctDNA).
  • One recent study showed that CRC screening rates tripled among adults who had declined prior CRC screening when they were offered Shield.